VANCOUVER, BC / TheNewswire / March 9, 2017 – Invictus MD Strategies Corp. (CSE: IMH; OTC: IVITF; FRA: 8IS).
Mr. Dan Kriznic, director of Invictus MD Strategies Corp. (the “Issuer”), announces that on March 2, 2017, he was granted stock options (the “Options”) to purchase 1,000,000 common shares of the Issuer exercisable at a price of $1.75 per common share on or before March 2, 2022.
Prior to the grant of Options, Mr. Kriznic had ownership and control, directly and indirectly, of 2,308,204 common shares, 85,000 warrants and 1,555,000 stock options of the Issuer, representing approximately 6.07% of the issued and outstanding common shares of the Issuer on a non-diluted basis and approximately 9.96% of the issued and outstanding common shares of the Issuer when assuming exercise of all 85,000 warrants and 1,555,000 stock options held by Mr. Kriznic.

Immediately after the grant of Options, Mr. Kriznic had ownership and control, directly and indirectly, of 2,308,204 common shares, 85,000 warrants and 2,555,000 stock options of the Issuer, representing approximately 6.07% of the issued and outstanding common shares of the Issuer on a non-diluted basis and approximately 12.17% of the issued and outstanding common shares of the Issuer when assuming exercise of all 85,000 warrants and 2,555,000 stock options held by Mr. Kriznic.
A copy of the early warning report in respect of the foregoing matters has been filed under the Issuer’s profile on the System for Electronic Document Analysis and Review (SEDAR) at www.sedar.com. You may also contact Dan Kriznic, Chairman & CEO of the Issuer, in order to obtain a copy of the early warning report at Suite 3123 – 595 Burrard Street, PO Box 49139, Three Bentall Centre, Vancouver, BC V7X 1J1 or at (604) 368-6437.
About Invictus MD Strategies Corp.
Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
604-368-6437
Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676


Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less